Motilal Oswal

FINANCIAL SERVICES

Gland Pharma

Estimate change	Ļ
TP change	Ļ
Rating change	\longleftrightarrow

Bloomberg	GLAND IN
Equity Shares (m)	165
M.Cap.(INRb)/(USDb)	265.4 / 3.2
52-Week Range (INR)	2221 / 1504
1, 6, 12 Rel. Per (%)	-4/-11/-18
12M Avg Val (INR M)	798

Financials & Valuations (INR b)

Y/E MARCH	FY25E	FY26E	FY27E
Sales	59.8	67.1	75.3
EBITDA	13.4	15.7	18.0
Adj. PAT	8.1	9.9	11.7
EBITDA Margin (%)	22.4	23.4	23.9
Cons. Adj. EPS (INR)	49.3	60.2	71.2
EPS Gr. (%)	3.6	22.1	18.2
BV/Sh. (INR)	579.0	639.2	710.4
Ratios			
Net D:E	(0.2)	(0.1)	(0.2)
RoE (%)	8.9	9.9	10.5
RoCE (%)	8.7	9.6	10.2
Payout (%)	-	-	-
Valuations			
P/E (x)	32.5	26.6	22.5
EV/EBITDA (x)	19.0	16.2	13.9
Div. Yield (%)	-	-	-
FCF Yield (%)	(3.1)	(1.0)	0.5
EV/Sales (x)	4.3	3.8	3.3

Shareholding Pattern (%)

As On	Sep-24	Jun-24	Sep-23				
Promoter	51.8	51.8	57.9				
DII	35.4	32.8	22.5				
FII	4.5	6.9	4.9				
Others	8.3	8.5	14.8				
Ell includes depository receipts							

FII includes depository receipts

CMP: INR1,611

TP: INR1,970 (+22%)

Buy

2Q beat due to controlled costs; Base business yet to witness revival

Cenexi's EBITDA break-even guidance for 4QFY25 intact

- Gland Pharma (GLAND) delivered better-than-expected operational performance for the quarter. Despite increased EBITDA loss at Cenexi YoY/QoQ and a lower share of the milestone income, the overall EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.
- We cut our earnings estimate by 8%/10%/7% for FY25/FY26/FY27 to factor in: a) the slowdown in US sales on account of a delay in potential approval and subsequent launches, b) gradual up-tick in the biologics business, and c) lower business due to a temporary setback at the Belgium site of Cenexi. We value GLAND at 30x 12M forward earnings to arrive at a TP of INR1,970.
- With two years of earnings decline in FY23/FY24, we believe the earnings are largely at trough and expected to experience revival over FY25-27. We expect 20% earnings CAGR over FY25-27, led by a) increased volume offtake of base products such as enoxaparin, b) EBITDA break-even of Cenexi and subsequent better operating leverage, c) additional business in the biologics segment, and d) commercialization of new products in the core market segment. Considering this outlook and stock trading at 16x/14x FY26/FY27 EV/EBITDA and 27x/22.5x FY26/FY27 PE, we reiterate BUY.

Ex-Cenexi business EBITDA margin stable YoY/up 500bp QoQ; Cenexi operational loss escalates YoY/QoQ

- GLAND's 2QFY25 revenues grew 2.4% YoY to INR14b (in-line with estimates). The base business (ex-Cenexi) grew 5% YoY to INR10.7b for the quarter. Core market sales grew 3.2% YoY to INR10.5b (75% of sales). RoW sales were flat on a YoY basis to INR2.7b (19% of sales). India sales were flat on a YoY basis to INR874m (6% of sales).
- Gross Margin (GM) contracted 240bp YoY to 59.1% due to a change in the product mix.
- EBITDA margin contracted 250bp YoY to 21.1% (our estimate: 19.6%), led by higher employee costs (up 130bp YoY as % of sales) offset by lower other expenses on a YoY basis by 180bp as a % of sales. On an ex-Cenexi basis, the EBITDA margin was 34.2% (Flat on a YoY basis /+ 520bp QoQ).
- Consequently, EBITDA declined 8.3% YoY to INR3b (our est: INR2.8b).
- Adj. PAT declined 16% YoY to INR1.6b (our est: INR1.5b) due to tax expense.
- In 1HFY25, revenue grew 8.7% YoY to INR28b while EBITDA/PAT declined 9.2%/20.8% YoY to INR5.6b/INR3b, respectively. We expect 3%/6%/27% YoY growth in Revenue/EBITDA/PAT to INR32b/INR8b/INR5b for 2HFY25.

Highlights from the management commentary

- GLAND indicated a low double-digit YoY growth in the sales of core markets for FY25.
- The company reiterated for EBITDA break-even in the Cenexi business by 4QFY25.
- With a new biologics agreement with DRL, GLAND expects commercial operations to commence from 1QFY26.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst - Akash Manish Dobhada (Akash.Dobhada@MotilalOswal.com) | Viraj Shah (Viraj.Shah@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report. Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

MOTILAL OSWAL

Consol Quarterly Porf

Consol Quarterly Perf.												(INR m)
Y/E March		FY	24			FY2	25E		FY24	FY25E	FY2	25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var. (%)
Net Sales	12,087	13,734	15,452	15,375	14,017	14,058	15,017	16,696	56,647	59,788	14,033	0.2
YoY Change (%)	41.1	31.5	64.7	95.9	16.0	2.4	-2.8	8.6	56.3	5.5	2.2	
Total Expenditure	9,147	10,493	11,710	11,788	11,373	11,088	11,593	12,341	43,138	46,395	11,282	
EBITDA	2,940	3,241	3,742	3,587	2,644	2,970	3,424	4,355	13,509	13,392	2,750	8.0
YoY Change (%)	8.9	5.3	29.2	113.0	-10.1	-8.3	-8.5	21.4	30.4	-0.9	-15.1	
Margins (%)	24.3	23.6	24.2	23.3	18.9	21.1	22.8	26.1	23.8	22.4	19.6	
Depreciation	653	813	1,053	926	920	938	970	996	3,446	3,823	960	
Interest	49	60	53	100	56	61	40	29	262	186	19	
Other Income	375	532	374	421	514	597	620	661	1,702	2,392	490	
PBT before EO expense	2,613	2,899	3,009	2,982	2,182	2,567	3,034	3,991	11,503	11,774	2,261	13.5
One-off income/(expense)	0	0	178	0	0	0	0	0	178	0	0	
РВТ	2,613	2,899	2,832	2,982	2,182	2,567	3,034	3,991	11,325	11,774	2,261	13.5
Тах	672	958	913	1,058	745	932	953	1,020	3,601	3,650	706	
Rate (%)	25.7	33.0	32.2	35.5	34.1	36.3	31.4	25.6	31.8	31.0	31.2	
Reported PAT	1,941	1,941	1,919	1,924	1,438	1,635	2,081	2,971	7,724	8,124	1,556	5.1
Adj PAT	1,941	1,941	2,039	1,918	1,438	1,635	2,081	2,971	7,839	8,124	1,556	5.1
YoY Change (%)	-15.3	-22.7	-12.1	61.7	-25.9	-15.8	2.1	54.9	-5.6	3.6	-19.8	

E: MOFSL Estimates

Key Performance Indicators (Consolidated)

Key Performance Indicators (Consolidated) (INI											(INR m)	
Y/E March	FY24					FY2	25E		FY24E	FY25E	FY25	Ε
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Core Markets	8,564	10,198	12,000	12,047	10,641	10,521	10,823	12,099	42,750	34,683	11,118	-5%
YoY Growth (%)	21.4	36.4	81.1	119.1	24.3	3.2	-9.8	0.4	59	-19	9.0	
India	647	876	761	526	527	874	685	724	2,810	2,810	569	53%
YoY Growth (%)	26.9	20.7	-6.5	-18.7	-18.5	-0.2	-10.0	37.7	12	0	-35.0	
Rest of the world	2,876	2,660	2,842	2,802	2,734	2,663	3 <i>,</i> 509	3,873	11,239	6,524	2,345	14%
YoY Growth (%)	187.0	18.6	46.3	64.3	-4.9	0.1	23.5	38.2	61	-42	-11.8	
Cost Break-up												
RM Cost (% of Sales)	37.5	38.0	38.8	39.0	40.3	40.9	40.4	39.7	38.4	40.3	40.0	93
Staff Cost (% of Sales)	21.1	22.2	22.3	22.9	25.4	23.5	22.1	19.6	22.2	22.5	25.0	(154)
Other Cost (% of Sales)	17.1	16.2	14.7	14.8	15.5	14.5	14.7	14.6	15.6	14.8	15.4	(92)
Gross Margins(%)	62.5	62.0	61.2	61.0	59.7	59.1	59.6	60.3	61.6	59.7	60.0	(93)
EBITDA Margins(%)	24.3	23.6	24.2	23.3	18.9	21.1	22.8	26.1	23.8	22.4	19.6	153
EBIT Margins(%)	18.9	17.7	17.4	17.3	12.3	14.5	16.3	20.1	17.8	22.1	12.8	170



Management call highlights

- GLAND has signed contracts related to GLP-1 products for the regulated market with three companies to date.
- Contribution from new products for the 1HFY25 was INR600m.
- GLAND indicated a potential pick-up in US sales in the coming quarters on account of additional contracts of Enoxaparin, new launches, and higher offtake of existing products.
- Gross margins have contracted YoY/QoQ for the Cenexi business due to a lower offtake of the Belgium site and a change in product mix.
- The profit share of the Cenexi business was 8% of sales and milestone income for Non-Cenexi business was 7% of sales during the quarter.
- The recent agreement with Dr. Reddy's Lab is largely toward supplying drug substances.
- A pick-up in the tender business for the Saudi Arabian market would support growth in the ROW market.
- Four molecules, including Cetrorelix Acetate, Ephedrine Sulfate, Tranexamic Acid, and Diazepam, were launched in the US market.
- A new ampoule line will be commissioned in Jan'25.

• Four of the nine products in the plan for the Chinese markets are currently under development, and five have received approvals.

Efforts underway to improve the overall profitability

New approvals remain the key to drive core market performance


- In 1HFY25, GLAND's base business (ex-Cenexi) grew 15% YoY to INR16.3b. Including Cenexi, the overall business grew 12.8% YoY to INR21.2b.
- The growth is fueled by volume growth in key injectables, new product launches, and market leadership of existing products.
- During 1HFY25, GLAND filed 15 ANDAs. It also received approvals for 15 products and launched 15 products (including SKUs).
- Moreover, GLAND is witnessing traction in the biologics space for advancedstage CDMO contracts in monoclonal antibodies and novel plasma-based proteins. Further, it has collaborated with DRRD for biologics and CDMO expects to commence the operation in FY26.
- With improving operational efficiency at Cenexi's facility, GLAND is expanding its capacity to enhance growth prospects.
- Overall, we expect 11% sales CAGR in the base business to reach INR43b over FY25-27. This would be supported by additional sales of Cenexi, which is likely to grow at 8.5% and reach INR18.6b over FY25-27.


Tender business/new launches to drive ROW growth prospects

- In 1HFY25, the RoW market witnessed a 2.5% YoY decline to INR5.4b. This growth was hit by inherent fluctuations in the business and a delay in tender procurements by partners to subsequent months.
- GLAND registered Ziprasidone, Furosemide, Deferoxamine, and Dexmedetomidine in new geographies during the quarter.
- Over FY25-27, we expect ROW sales to report 17% CAGR and reach ~INR9b, led by expansion in new geographies and new launches.


Reiterate BUY

- We cut our earnings estimate by 8%/10%/7% for FY25/FY26/FY27 to factor in: a) the slowdown in US sales on account of a delay in the potential approval and subsequent launches, b) gradual up-tick in the biologics business, and c) lower business due to a temporary setback at the Belgium site of Cenexi. We value GLAND at 30x 12M forward earnings to arrive at a TP of INR1,970.
- With two years of earnings decline in FY23/FY24, we believe the earnings are largely at trough and expected to witness revival over FY25-27. We expect 20% earnings CAGR over FY25-27, led by a) increased volume offtake of base products such as enoxaparin, b) EBITDA break-even of Cenexi and subsequent better operating leverage, c) additional business in the biologics segment, and d) commercialization of new products in the core market segment. Considering this outlook and stock trading at 16x/14x FY26/FY27 EV/EBITDA and 27x/22.5x FY26/FY27 PE, we reiterate BUY.













Exhibit 8: Expect EPS CAGR of 20% over FY25-27



Financials and valuations

Consolidated - Income Statement									(INRm
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Total Income from Operations	20,442	26,332	34,629	44,007	36,246	56,647	59,788	67,136	75,284
Change (%)	26.0	28.8	31.5	27.1	-17.6	56.3	5.5	12.3	12.1
Total Expenditure	13,376	16,778	21,607	28,906	25,888	43,138	46,395	51,426	57,291
% of Sales	65.4	63.7	62.4	65.7	71.4	76.2	77.6	76.6	76.1
EBITDA	7,066	9,554	13,022	15,102	10,358	13,509	13,392	15,710	17,993
Margin (%)	34.6	36.3	37.6	34.3	28.6	23.8	22.4	23.4	23.9
Depreciation	820	946	988	1,103	1,467	3,446	3,823	4,058	4,198
EBIT	6,246	8,608	12,034	13,999	8,890	10,063	9,569	11,652	13,795
Int. and Finance Charges	36	72	34	52	74	262	186	67	56
Other Income	856	1,392	1,348	2,239	2,405	1,702	2,392	2,685	3,011
PBT bef. EO Exp.	7,067	9,928	13,348	16,186	11,220	11,503	11,774	14,270	16,750
EO Items	-200	0	0	0	-685	178	0	0	0
PBT after EO Exp.	6,867	9,928	13,348	16,186	10,536	11,325	11,774	14,270	16,750
Total Tax	2,345	2,200	3,378	4,069	2,735	3,601	3,650	4,352	5,025
Tax Rate (%)	34.1	22.2	25.3	25.1	26.0	31.8	31.0	30.5	30.0
Minority Interest	0	0	0	0	0	0	0	0	0
Reported PAT	4,522	7,728	9,970	12,117	7,800	7,724	8,124	9,918	11,725
Adjusted PAT	4,654	7,728	9,970	12,117	8,307	7,839	8,124	9,918	11,725
Change (%)	44.8	66.1	29.0	21.5	-31.4	-5.6	3.6	22.1	18.2
Margin (%)	21.9	27.9	25.0	26.2	21.5	13.4	13.1	14.2	15.0
	21.5	27.0	27.7	20.2	21.5	10.1	10.1	1.1.2	10.0
Consolidated - Balance Sheet									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity Share Capital	155	155	164	164	165	165	165	165	165
Total Reserves	28,466	36,307	58,869	71,412	79,423	87,074	95,198	1,05,116	1,16,841
Net Worth	28,400	36,462	59,032	71,576	79,587	87,238	95,363	1,05,110 1,05,281	1,17,006
Minority Interest	0	0	0	0	0	07,230	0	1,03,201	1,17,000
Total Loans	55	50	39	46	45	3,722	3,722	3,722	3,722
Deferred Tax Liabilities	1,076	741	739	878	842	1,697	1,697	1,697	1,697
Capital Employed	29,752	37,252	59,810	72,499	80,473	92,656	1,00,781	1,10,699	1,22,424
Gross Block	12,196	13,478	14,327	20,910	23,061	47,846	58,361	70,465	76,837
							•	•	
Less: Accum. Deprn. Net Fixed Assets	2,908	3,797	4,785	5,888	7,355	10,801	14,624	18,682	22,880
Goodwill on Consolidation	9,288 0	9,681 0	9,542 0	15,022 0	15,705 0	37,045	43,737 0	51,782 0	53,957
Capital WIP			3,378			2,423			0
	1,232	1,885	,	1,907	1,772	2,379	9,088	6,650	2,383
Total Investments	0	0	0	1,549	0	6,559	6,559	6,559	6,559
Curr. Assets, Loans&Adv.	24,707	29,295	52,040	59,858	70,298	57,703	55,767	62,415	76,977
Inventory	9,119	7,563	12,752	11,857	19,453	16,552	20,592	24,656	29,352
Account Receivables	5,061	6,018	6,710	11,988	8,714	15,587	15,070	16,738	19,595
Cash and Bank Balance	7,534	13,252	30,058	30,934	37,707	18,394	12,539	12,525	16,738
Loans and Advances	2,994	2,462	2,521	5,079	4,424	7,169	7,567	8,496	11,293
Curr. Liability & Prov.	5,473	3,608	5,150	5,836	7,302	13,451	14,370	16,707	17,450
Account Payables	4,568	2,677	4,007	4,629	5,874	8,627	9,278	10,990	12,557
Other Current Liabilities	765	649	892	960	1,115	2,863	3,022	3,393	3,011
Provisions	139	282	251	248	313	1,961	2,070	2,324	1,882
Net Current Assets	19,234	25,687	46,890	54,022	62,997	44,252	41,397	45,708	59,526
Deferred Tax assets	0	0	0	0	0	0	0	0	0
Misc Expenditure	0	0	0	0	0	0	0	0	0
Appl. of Funds	29,752	37,252	59,810	72,499	80,473	92,656	1,00,781	1,10,699	1,22,424

E: MOFSL Estimates

Financials and valuations

Ratios									
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Basic (INR)									
EPS	28.3	46.9	60.5	73.6	50.4	47.6	49.3	60.2	71.2
Cash EPS	35.3	56.0	67.0	80.5	59.3	68.5	72.5	84.9	96.7
BV/Share	184.7	235.2	360.9	435.6	483.2	529.7	579.0	639.2	710.4
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Valuation (x)									
P/E	56.7	34.1	26.5	21.8	31.8	33.7	32.5	26.6	22.5
Cash P/E	45.4	28.6	23.9	19.9	27.0	23.4	22.1	18.9	16.6
P/BV	8.7	6.8	4.4	3.7	3.3	3.0	2.8	2.5	2.3
EV/Sales	11.8	8.9	6.7	5.3	6.2	4.4	4.3	3.8	3.3
EV/EBITDA	34.1	24.6	17.8	15.4	21.8	18.4	19.0	16.2	13.9
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	3.2	34.2	23.0	17.0	8.6	-25.6	-48.9	-16.0	7.6
Return Ratios (%)									
RoE	17.7	23.7	20.9	18.6	11.0	9.4	8.9	9.9	10.5
RoCE	17.7	23.9	20.9	18.6	11.1	9.4	8.7	9.6	10.2
RoIC	21.9	31.2	37.1	32.5	16.6	12.9	9.6	10.3	10.6
Working Capital Ratios									
Asset Turnover (x)	1.7	2.0	2.4	2.1	1.6	1.2	1.0	1.0	1.0
Inventory (Days)	163	116	134	98	196	107	126	134	142
Debtor (Days)	90	83	71	99	88	100	92	91	95
Creditor (Days)	82	37	42	38	59	56	57	60	61
Leverage Ratio (x)									
Net Debt/Equity	-0.3	-0.4	-0.5	-0.45	-0.47	-0.2	-0.2	-0.1	-0.2
Consolidated - Cash Flow Statement									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
OP/(Loss) before Tax	6,864	9,929	13,348	16,186	10,546	11,325	11,774	14,270	16,750
Depreciation	820	, 946	988	1,103	1,467	3,446	3,823	4,058	4,198

	-,	- ,- =-		,	/		,	,	
Depreciation	820	946	988	1,103	1,467	3,446	3,823	4,058	4,198
Interest & Finance Charges/ (Income)	-408	-452	28	33	63	218	-2,205	-2,618	-2,956
Direct Taxes Paid	-2,235	-2,441	-3,114	-4,065	-3,109	-3,061	-3,650	-4,352	-5,025
(Inc)/Dec in WC	-3,540	-799	-4,358	-3,931	-4,179	-532	-3,001	-4,325	-9,605
CF from Operations	1,501	7,181	6,893	9,326	4,788	11,396	6,741	7,032	3,363
Others	350	-172	-843	-1,418	-1,148	-1,428	0	0	0
CF from Operating incl EO	1,851	7,009	6,049	7,908	3,640	9,968	6,741	7,032	3,363
(Inc)/Dec in FA	-1,352	-1,708	-2,283	-5,113	-2,230	-14,192	-14,802	-9,665	-2,105
Free Cash Flow	499	5,302	3,766	2,794	1,410	-4,224	-8,061	-2,633	1,258
(Pur)/Sale of Investments	0	0	-13,576	-2,613	12,706	-4,747	0	0	0
Others	-1,834	-5,902	619	-2,300	1,606	1,371	2,392	2,685	3,011
CF from Investments	-3,186	-7,610	-15,240	- 10,02 6	12,082	-17,569	-12,411	-6,980	906
Issue of Shares	0	0	12,250	0	215	5	0	0	0
Inc/(Dec) in Debt	-4	-7	-9	-1	-3	-7,743	0	0	0
Interest Paid	-25	-62	-23	-33	-63	-256	-186	-67	-56
Dividend Paid	0	0	0	0	0	0	0	0	0
CF from Fin. Activity	-29	-69	1 2,38 6	320	-8,949	-11,711	-186	-67	-56
Inc/Dec of Cash	-1,364	-669	3,195	-1,799	6,773	-19,312	-5,856	-14	4,213
Opening Balance	3,728	2,363	1,694	4,889	3,091	9,863	-9,449	-15,305	-15,319
Closing Balance	2,363	1,694	4,889	3,091	9,863	-9,449	-15,305	-15,319	-11,106
Term Deposit with Banks	5,170	11,558	25,168	27,844	27,844	27,844	27,844	27,844	27,844
Total Cash & Cash Eq	7,533	13,252	30,057	30,934	37,707	18,395	12,539	12,525	16,738

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating							
Investment Rating	Expected return (over 12-month)						
BUY	>=15%						
SELL	< - 10%						
NEUTRAL	< - 10 % to 15%						
UNDER REVIEW	Rating may undergo a change						
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation						

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinere s.motil

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage transactions. Details of pending Enquiry Proce laxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx Enquiry Proceedings of Motilal Oswal Limited Financial Services available website service are on the

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong. For U.S.

Motifal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com Contact: (+65) 8328 0276

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report 4
- Research Analyst has not served as director/officer/employee in the subject company 5
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months 6
- MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months 8
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085. Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent - CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com